Bayer taps PeptiDream in multi-target discovery alliance

20-Nov-2017 - Last updated on 20-Nov-2017 at 16:59 GMT

(Image: iStock/GernardaSv)

Related tags Protein

Kanagawa-based PeptiDream’s drug discovery alliance with Bayer AG is a deal potentially worth up to $1.11bn, according to the company.

According to PeptiDream Inc., its proprietary peptide discovery platform system (PDPS) enables the production of diverse non-standard peptide libraries for the identification of highly potent and selective hit candidates.

As part of its discovery collaboration with Germany-based Bayer AG, PeptiDream will use its PDPS technology to identify macrocyclic/constrained peptides – generally defined as cyclic small molecules – against multiple targets selected by Bayer.

Patrick Reid, CEO of PeptiDream said in a press release that the agreement is “one of the broadest discovery deals PeptiDream has entered into.” The agreement covers peptide therapeutics and small molecule therapeutics, and options to peptide drug conjugates (PDCs), diagnostic agents, bioimaging agents, and more, he said.

According to PeptiDream, Bayer also has the option to negotiate for an extension of the license to peptide-drug conjugate (PDC), diagnostic, bioimaging, and agricultural use and applications.

Bayer has the right to develop and commercialize all compounds resulting from the collaboration, for which PeptiDream is eligible to receive royalties.

PeptiDream will receive an undisclosed upfront payment and research funding and is eligible to receive preclinical, clinical, and commercialization milestone payments potentially reaching up to $1.11bn (¥124.5bn).